• shareshare
  • link
  • cite
  • add
auto_awesome_motion View all 2 versions
Publication . Article . 2011

Allopurinol pharmacogenetics: assessment of potential clinical usefulness

Issam Zineh; Padmaja Mummaneni; Jenna Lyndly; Shashi Amur; Lois La Grenade; Stephen H Chang; Hobart Rogers; +1 Authors
Open Access
Published: 01 Dec 2011
Publisher: Zenodo

Use of pharmacogenetics to inform treatment decisions remains a priority for clinicians, patients and public health agencies. We previously developed a framework for systematically assessing whether pharmacogenetic test information would likely bring value to clinical decision-making and enjoy practical uptake. We applied this tool to allopurinol to determine potential usefulness of HLA genetic information in assessing risk for allopurinol-induced severe cutaneous adverse reactions. We quantified allopurinol use data and the magnitude of adverse event signals using US FDA databases, reviewed reported cases of allopurinol-associated severe cutaneous adverse reactions to assess whether clinical subtypes of patients could be identified, performed pooled analyses of associations between HLA variation and allopurinol-induced severe cutaneous adverse reactions and described considerations in clinical implementation of allopurinol pharmacogenetics.

Subjects by Vocabulary

Medical Subject Headings: musculoskeletal diseases

Microsoft Academic Graph classification: Allopurinol medicine.drug medicine Risk assessment Pharmacogenetic Test Pharmacology Adverse effect Treatment decision making Intensive care medicine medicine.medical_specialty Public health MEDLINE Pharmacogenetics business.industry business


Pharmacology, Genetics, Molecular Medicine